Charlotte Ballard
Primary Care · San Antonio, TXNPI 1902893324
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 512 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,060 and has fallen 74.8% since, to $770 in 2025. Among primary care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 512 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$2K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$513
- plus $1K from 13 others
What the payments were for
- Travel & lodging$190%
- Food & beverage$8,76698%
- Education$1672%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 114 | $1,838 |
| Alkermes, Inc. | 89 | $1,531 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 64 | $1,317 |
| Teva Pharmaceuticals USA, Inc. | 76 | $1,252 |
| Johnson & Johnson | 69 | $1,199 |
| Otsuka America Pharmaceutical, Inc. | 36 | $513 |
| AbbVie | 12 | $280 |
| E.r. Squibb & Sons, L.L.C. | 7 | $216 |
| Eisai Inc. | 10 | $172 |
| Avanir Pharmaceuticals, Inc. | 8 | $125 |
| Sumitomo Pharma America, Inc. | 7 | $124 |
| Indivior Inc. | 4 | $90 |
| SK Life Science, Inc. | 5 | $80 |
| Neurocrine Biosciences, Inc. | 4 | $76 |
| GSK | 3 | $50 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Aquestive Therapeutics, Inc. | 1 | $21 |
| UCB, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,952 in reported general payments places this provider in the 95th percentile of 563 primary care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 223 | $648,086 |
| Invega TrinzaPaliperidone Palmitate | 53 | $543,010 |
| AristadaAripiprazole Lauroxil | 78 | $279,194 |
| AustedoDeutetrabenazine | 41 | $270,798 |
| LybalviOlanzapine/Samidorphan Malate | 108 | $181,359 |
| NuedextaDextromethorphan Hbr/Quinidine | 94 | $153,130 |
| AptiomEslicarbazepine Acetate | 59 | $81,606 |
| RexultiBrexpiprazole | 26 | $36,159 |
| Oxcarbazepine | 444 | $30,942 |
| LinzessLinaclotide | 51 | $29,029 |
| OzempicSemaglutide | 22 | $22,048 |
| Divalproex Sodium ErDivalproex Sodium | 249 | $16,364 |
| JanuviaSitagliptin Phosphate | 27 | $16,164 |
| Oxtellar XrOxcarbazepine | 26 | $14,348 |
| Atomoxetine Hcl | 58 | $11,833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Xarelto | $1,199 | $1,196,479287 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,531 | $460,554186 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Loxapine | $1,252 | $274,17156 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $125 | $153,13094 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $1,838 | $81,60659 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $513 | $36,15926 claims |
| AbbVieLinzess | $280 | $29,02951 claims |
| GSKTrelegy Ellipta | $50 | $7,34311 claims |
| Lilly USA, LLCOlanzapine | $18 | $3,065170 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 563 primary care providers in Texas.
Other primary care in San Antonio
- Phillip GulleySan Antonio$23K
- Christopher LoganSan Antonio$8K
- Lydia Chapa WilsonSan Antonio$7K
- Jing LiSan Antonio$6K
- Lauryn SaenzSan Antonio$5K
- Brittany CurrySan Antonio$4K
- Martha RuizSan Antonio$3K
- Ryan WenclSan Antonio$3K
- Gabriella MutschlechnerSan Antonio$3K
- Mary GibbensHouston$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.